News
(3)April 2026
Trevi Therapeutics: Full Filing Text is Required for Analysis
I am unable to summarize the filing because the actual document content was not provided. The structured tags indicated a filing (`<PDF></PDF>`) but contained no text or data. Please provide the full text, or the PDF of, the SEC filing for Trevi Therapeutics, Inc. (TRVI). Once I receive the documen
TRVI proposes doubling authorized shares and expanding incentive stock pool
# 📑 What This Document Is 📰 This document is a Definitive Proxy Statement, which is essentially an official packet of instructions for the company's annual meeting. 👉 It tells stockholders exactly what topics will be voted on, who the leaders are, and how they must vote their shares. The filing d
Trevi Therapeutics TRVI Seeks Approval for Stock Plan and Share Increase
# 🧾 What This Document Is This is a **PRE 14A**, or **Preliminary Proxy Statement**. Think of it as a "preview" and an invitation. Trevi Therapeutics is sending it to its shareholders ahead of the **2026 Annual Meeting**. Its job is to explain what will be voted on, provide background info, and rec
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.